CD38-specific CAR-T cell therapy has also been shown to be effective in vitro and in vivo against hematological malignancies such as myeloma and B-cell non-Hodgkin’s lymphoma [163, 164]. This evidence concerns the gene CD38 and plasma cell myeloma.